149 related articles for article (PubMed ID: 26583773)
1. Cryosurgery during Imiquimod (Immunocryosurgery) for Periocular Basal Cell Carcinomas: An Efficacious Minimally Invasive Treatment Alternative.
Gaitanis G; Kalogeropoulos CD; Bassukas ID
Dermatology; 2016; 232(1):17-21. PubMed ID: 26583773
[TBL] [Abstract][Full Text] [Related]
2. Immunocryosurgery for non-superficial basal cell carcinoma: a pro-spective, open-label phase III study for tumours ≤ 2 cm in diameter.
Gaitanis G; Bassukas ID
Acta Derm Venereol; 2014 Jan; 94(1):38-44. PubMed ID: 23722308
[TBL] [Abstract][Full Text] [Related]
3. Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application.
Gaitanis G; Nomikos K; Vava E; Alexopoulos EC; Bassukas ID
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1427-31. PubMed ID: 19555364
[TBL] [Abstract][Full Text] [Related]
4. Office-based treatment of basal cell carcinoma with immunocryosurgery: feasibility and efficacy.
Nakuçi M; Bassukas ID
Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):35-8. PubMed ID: 23836356
[TBL] [Abstract][Full Text] [Related]
5. Immunocryosurgery for non-superficial basal cell carcinomas ≤ 20 mm in maximal diameter: Five-year follow-up.
Gaitanis G; Bassukas ID
J Geriatr Oncol; 2019 May; 10(3):475-478. PubMed ID: 30219274
[TBL] [Abstract][Full Text] [Related]
6. Immunocryosurgery - an effective combinational modality for Bowen's disease.
Gaitanis G; Bassukas ID
Dermatol Ther; 2016 Sep; 29(5):334-337. PubMed ID: 27272913
[TBL] [Abstract][Full Text] [Related]
7. The Feasibility of Immunocryosurgery in the Treatment of Non-Superficial, Facial Basal Cell Carcinoma That Relapsed after Standard Surgical Excision: An Experience Report from Two Centers.
Gaitanis G; Zampeta A; Tsintzou P; Fillis G; Seretis K; Feldmeyer L; Bassukas I
Curr Oncol; 2022 Nov; 29(11):8475-8482. PubMed ID: 36354728
[TBL] [Abstract][Full Text] [Related]
8. Cryosurgery is more effective in the treatment of primary, non-superficial basal cell carcinomas when applied during and not prior to a five week imiquimod course: a randomized, prospective, open-label study.
Gaitanis G; Alexopoulos EC; Bassukas ID
Eur J Dermatol; 2011; 21(6):952-8. PubMed ID: 21926038
[TBL] [Abstract][Full Text] [Related]
9. Immunocryosurgery is a safe and feasible treatment for basal cell carcinoma and Bowen disease in renal transplant recipients.
Tsironi T; Gaitanis G; Pappas C; Koutlas V; Dounousi E; Bassukas ID
Dermatol Ther; 2022 May; 35(5):e15405. PubMed ID: 35194902
[TBL] [Abstract][Full Text] [Related]
10. Imiquimod can be combined with cryosurgery (immunocryosurgery) for locally advanced periocular basal cell carcinomas.
Gaitanis G; Kalogeropoulos C; Bassukas ID
Br J Ophthalmol; 2011 Jun; 95(6):890-2. PubMed ID: 21378006
[No Abstract] [Full Text] [Related]
11. Alterations in the inflammatory cells infiltrating basal cell carcinomas during immunocryosurgery.
Nomikos K; Lampri E; Spyridonos P; Bassukas ID
Arch Dermatol Res; 2019 Aug; 311(6):499-504. PubMed ID: 31115658
[TBL] [Abstract][Full Text] [Related]
12. Intralesional bevacizumab as in-add adjuvant to immunocryosurgery for locally advanced basal cell carcinoma.
Gaitanis G; Bassukas I
J Eur Acad Dermatol Venereol; 2014 Aug; 28(8):1117-21. PubMed ID: 25243268
[TBL] [Abstract][Full Text] [Related]
13. Large facial basal cell carcinoma treated with multimodal combination therapy.
Rubenzik MK; Schwartz LR; Humphreys TR
Cutis; 2011 Oct; 88(4):182-4. PubMed ID: 22106726
[TBL] [Abstract][Full Text] [Related]
14. Treatment of nodular basal cell carcinoma with cryotherapy and reduced protocol of imiquimod.
Moutran R; Maatouk I; Stephan F; Tomb R
Cutis; 2012 Nov; 90(5):256-7. PubMed ID: 23270198
[TBL] [Abstract][Full Text] [Related]
15. Immunocryosurgery for patients with therapeutically challenging basal cell carcinomas: report of two representative cases.
Gaitanis G; Nomikos K; Vlachos C; Bassukas ID
J Dermatolog Treat; 2012 Feb; 23(1):70-1. PubMed ID: 20964570
[No Abstract] [Full Text] [Related]
16. Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas.
Garcia-Martin E; Idoipe M; Gil LM; Pueyo V; Alfaro J; Pablo LE; Zubiri ML; Fernandez J
J Ocul Pharmacol Ther; 2010 Aug; 26(4):373-9. PubMed ID: 20698800
[TBL] [Abstract][Full Text] [Related]
17. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma.
Tillman DK; Carroll MT
J Drugs Dermatol; 2008 Jan; 7(1 Suppl 1):s7-14. PubMed ID: 18277457
[TBL] [Abstract][Full Text] [Related]
18. Bowen's disease of the digit successfully treated with immunocryosurgery.
Benmously-Mlika R; Hammami-Ghorbel H; Koubaa W; Debbiche A; Mokhtar I
Int J Dermatol; 2013 Apr; 52(4):514-6. PubMed ID: 23046474
[No Abstract] [Full Text] [Related]
19. Immunocryosurgery for basal cell carcinoma: impact on circulating CD4
Gaitanis G; Ganiatsa A; Vartholomatos G; Karamoutsios A; Pappas P; Bassukas ID
Eur J Dermatol; 2020 Oct; 30(5):605-606. PubMed ID: 32959782
[No Abstract] [Full Text] [Related]
20. Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy.
Warshauer E; Warshauer BL
J Drugs Dermatol; 2008 May; 7(5):447-51. PubMed ID: 18505136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
